Diagenode

News

With RNAi across the hemophilia
October 23, 2015

RNA interference (RNAi) may be used as a therapeutic for the bleeding disorder hemophilia. Specifically, artificially-generated, epigenetically-activated RNA molecules such as microRNAs can be used to inhibit gene expression through post-translational gene silencing. Researchers from France and the USA recently treated hemophiliac mice and macaques with a successful RNAi compound (ALN-AT3), which supresses the production of the anti-clotting substance antithrombin. Currently this therapeutic is being investigated in phase 1 clinical trials in individuals with hemophilia A or B.

Source: http://www.newsletter-epigenetik.de/

Read more

Events

  • Stem Cell Symposium
    Cambridge
    Sep 19-Sep 21, 2018
  • 2018 PacBio User Group Meeting (UGM)
    St Louis
    Sep 19-Sep 20, 2018
  • Livestock Genomics IV
    Wellcome Genome Campus, Hinxton, Cambridge, UK
    Sep 21-Sep 22, 2018
 See all events

Applications

 See all applications



The European Regional Development Fund and Wallonia are investing in your future.

Extension of industrial buildings and new laboratories.



  ABOUT SSL CERTIFICATES

         Site map   |   Contact us   |   Conditions of sales   |   Conditions of purchase   |   Privacy policy   |   Diagenode Diagnostics